Extramedullary Plasmacytoma Causing Myelopathy Resulting in Gait Imbalance.

cd 138 immunostain extramedullary plasmacytoma international myeloma working group radiotherapy (rt) spinal cord compression

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
22 May 2021
Historique:
entrez: 25 6 2021
pubmed: 26 6 2021
medline: 26 6 2021
Statut: epublish

Résumé

Plasmacytomas are neoplasms of plasma cells that can involve the bone marrow, the bone itself, or soft tissue without bone marrow involvement. Extramedullary plasmacytomas are most commonly found in the upper respiratory tract in a total of 80% of all cases. Extramedullary plasmacytomas have also been documented in locations such as the central nervous system. This form of plasmacytoma may be seen as a solitary entity or in patients with multiple myeloma. We present a case of a 66-year-old female with a history of multiple myeloma on maintenance therapy with lenalidomide who has been experiencing gait imbalance for the past two months. The patient had a thoracic MRI done that revealed a mass at T7-8 with associated cord compression. She was taken for surgical intervention by neurosurgery. Pathology revealed trabecular bone and cartilage infiltrated by sheets of plasma cells highlighted by immunostaining CD138, monoclonal lambda light chains, consistent with a plasma cell neoplasm (plasmacytoma). The patient's hospital course was complicated by hypotension resulting in transient ischemic myelopathy that was addressed in the neuro-intensive care unit. The patient was then discharged to an inpatient rehabilitation center. She would follow up with her primary oncologist for localized radiation therapy.

Identifiants

pubmed: 34168932
doi: 10.7759/cureus.15171
pmc: PMC8216312
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e15171

Informations de copyright

Copyright © 2021, Wert et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Int Med Res. 2016 Dec;44(6):1462-1473
pubmed: 28322099
BMJ Case Rep. 2017 Oct 19;2017:
pubmed: 29054949
Scand J Clin Lab Invest Suppl. 2016;245:S113-8
pubmed: 27467897
Curr Hematol Malig Rep. 2019 Apr;14(2):63-69
pubmed: 30788667
Haematologica. 2016 Apr;101(4):e142-4
pubmed: 26819048
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):794-808
pubmed: 29976492
Medicine (Baltimore). 2017 Jun;96(25):e7277
pubmed: 28640138
J Med Case Rep. 2018 Mar 18;12(1):70
pubmed: 29549883
J Med Case Rep. 2017 Aug 10;11(1):219
pubmed: 28793931
Eur J Haematol. 2019 May;102(5):389-394
pubmed: 30719772
Curr Hematol Malig Rep. 2018 Jun;13(3):227-235
pubmed: 29667156
Lancet. 2017 Nov 4;390(10107):2083
pubmed: 28844475
Ann Oncol. 2010 Feb;21(2):325-330
pubmed: 19633044
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696

Auteurs

James Wert (J)

Internal Medicine, AdventHealth Orlando, Orlando, USA.

Aimen Farooq (A)

Internal Medicine, AdventHealth Orlando, Orlando, USA.

Anum Jalil (A)

Internal Medicine, AdventHealth Orlando, Orlando, USA.

Classifications MeSH